November 2026 | Flash Note | BUY (affirmed) | Target price CZK 280 / EUR 11.49
Refinancing resolved, focus shifts to cash generation
GEVORKYAN’s H1 2026 results show continued growth: revenue rose 18% to EUR 49.8M and EBITDA 9% to EUR 15.0M, at a margin of 30.2%. The successful refinancing of the EUR 30M bond maturing in November 2026 removes the main near-term risk identified in our prior coverage. The new bond, issued directly by GEVORKYAN, a.s., carries a higher coupon of 7.39%.
With the refinancing behind it, the investment case now rests on execution. H1 free cash flow was EUR -9.8M, funded by the March equity raise, and Net Debt/LTM EBITDA stands at 3.2x, leaving limited covenant headroom. The key tests ahead are margin recovery after the consolidation of Gevorkyan Sinteris Italia and the expected free-cash-flow turn from 2027, as the investment cycle moves toward maintenance capex.
We affirm our BUY rating. The target price moves to CZK 280 / EUR 11.49 from CZK 292, reflecting updated net debt from the H1 balance sheet. The 9.7x EV/EBITDA multiple and valuation framework are unchanged.
Key figures
| Rating | BUY (affirmed) |
| Target price | CZK 280 / EUR 11.49 |
| Prior target | CZK 292 / EUR 12.02 |
| Valuation method | EV/EBITDA, 9.7x |
| H1 2026 revenue | EUR 49.8M (+18%) |
| H1 2026 EBITDA | EUR 15.0M (+9%) |
| Net Debt/LTM EBITDA | 3.2x |
| Rating validity | Until 9M 2026 results or a material event |
Download the full report (PDF)
The report is also available to institutional investors on LSEG Workspace.
This report has been commissioned by GEVORKYAN, a.s. (issuer-sponsored research). The analytical view and all conclusions are based solely on Gafrik Research s.r.o.’s independent analysis. This is not a personal investment recommendation. Recommendation history, rating definitions and methodology: www.gafrikresearch.com/methodology

